JP1 improved movement and survival in ALS model mice by targeting oxidative stress and autophagy
Original source
JP1 peptide modulates oxidative stress and autophagy via Keap1-Nrf2-ARE in ALS model mice. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Mouse
Related topics
In SOD1-G93A mice, the experimental peptide JP1 improved motor function and extended survival. It activated the Nrf2 pathway, reduced oxidative stress and neuronal damage, and restored autophagy. Blocking Nrf2 removed these protective effects.
Why this matters
JP1 is being investigated as a possible treatment approach that addresses several disease-related processes at once. These results are from a mouse model and do not yet show that JP1 is safe or effective for people with ALS, or that it changes current treatment.
Limitations and context
This was a preclinical study in SOD1-G93A model mice, not a human clinical trial. The findings still need to be tested for safety and effectiveness in people with ALS.
Relevant to you?